Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

PURPOSE: Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). PATIENTS...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Pietanza, M. Catherine, Waqar, Saiama N., Krug, Lee M., Dowlati, Afshin, Hann, Christine L., Chiappori, Alberto, Owonikoko, Taofeek K., Woo, Kaitlin M., Cardnell, Robert J., Fujimoto, Junya, Long, Lihong, Diao, Lixia, Wang, Jing, Bensman, Yevgeniva, Hurtado, Brenda, de Groot, Patricia, Sulman, Erik P., Wistuba, Ignacio I., Chen, Alice, Fleisher, Martin, Heymach, John V., Kris, Mark G., Rudin, Charles M., Byers, Lauren Averett
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2018
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6085179/
https://ncbi.nlm.nih.gov/pubmed/29906251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.7672
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы